Article
Mechanistic Analysis of the Broad Antiretroviral Resistance Conferred by HIV-1 Envelope Glycoprotein Mutations.
mBio - 12 Jan 2021
Hikichi Yuta, Van Duyne Rachel, Pham Phuong, Groebner Jennifer L, Wiegand Ann, Mellors John W, Kearney Mary F, Freed Eric O
Abstract excerpt
Despite the effectiveness of antiretroviral (ARV) therapy, virological failure can occur in some HIV-1-infected patients in the absence of mutations in drug target genes. We previously reported that, in vitro, the lab-adapted HIV-1 NL4-3 strain can acquire resistance to the integrase inhibitor dolutegravir (DTG) by acquiring mutations in the envelope glycoprotein (Env) that enhance viral cell-cell transmission....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.